Behtash Nadereh, Karimi Zarchi Mojgan
Gynecology Oncology Department, Vali-asr Hospital, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Keshavarz Boulevard, Tehran 14194, Iran.
J Cancer Res Clin Oncol. 2008 Jan;134(1):1-6. doi: 10.1007/s00432-007-0208-y. Epub 2007 Aug 16.
Placental site trophoblastic tumor (PSTT) is a rare neoplasm that rises from intermediate trophoblasts and commonly presents with low and variable concentration of HCG immunoactivity in serum, which can be difficult to differentiate from early stage choriocarcinoma/gestational trophoblastic neoplasm (GTN) or quiescent gestational trophoblastic disease. PSTT can occur after a normal pregnancy, spontaneous abortion, termination of pregnancy, ectopic or molar pregnancy. There is a wide clinical spectrum of presentation and behavior ranging from a benign condition to an aggressive disease with fatal outcome. Nontrophoblastic malignancies such as germ cell tumors or other tumors secreting low HCG must also be considered in the differential diagnosis. Because treatments for these conditions are different, a means of differentiating PSTT from other diagnoses is important. Surgery is the cornerstone of treatment. Chemotherapeutic regimen should be EMA/CO for first line chemotherapy; EMA/EP should be used in EMA/CO refractory cases. This article reviews the literatures on this rare but fatal disease.
胎盘部位滋养细胞肿瘤(PSTT)是一种罕见的肿瘤,起源于中间型滋养细胞,血清中HCG免疫活性浓度通常较低且变化不定,这可能难以与早期绒毛膜癌/妊娠滋养细胞肿瘤(GTN)或静止期妊娠滋养细胞疾病相鉴别。PSTT可发生于正常妊娠、自然流产、终止妊娠、异位妊娠或葡萄胎妊娠之后。其临床表现和行为范围广泛,从良性情况到具有致命结局的侵袭性疾病。在鉴别诊断中还必须考虑非滋养细胞恶性肿瘤,如生殖细胞肿瘤或其他分泌低水平HCG的肿瘤。由于这些疾病的治疗方法不同,区分PSTT与其他诊断的方法很重要。手术是治疗的基石。一线化疗的化疗方案应为EMA/CO;EMA/CO难治性病例应使用EMA/EP。本文综述了关于这种罕见但致命疾病的文献。